stady there	Solyroup within a	al Pater	and have point	Statut	on for end	h study		MH risk ratio and 95% Cl
		-		MI Low	e Unever			
			n	sk ratio limi	limit i	-Valup	-Value	
Pepe et al. 2015	Permuropophinal	TLR	12 months	0.14 0.4	6 0.54	-4.40	0.00	
Schemert et al. 201	4Femuropopliteal	TLR	12 months	0.81 0.4	4 1.49	-0.68	0.50	
amella et al. 2014	Infrapoplited	TLR	12 months	0.35 0.1	6 0.75	-2.70	0.61	
icheinert et al. 201	Wennropoplineal	TLR	12 months	0.38 0.1	4 1.06	-1.85	0.66	
Nerk et al. 2013	Fermiropophiesi	<b>TL</b> .H.	12 months	0.20 04	6 0.66	-2.67	0.81	
Fepe et al.2008	Ferruropophisal	TLR	12 months	0.17 0.0	0.41	-3.96	0.00	
Lintro et al. 2013 ;	2 intrapoplited	TLR	12 months	0.42 0.3	4 0.75	-2.93	0.00	
Lintro et al. 2013 (	1Femreopophteal	TI.R.	12 months	0.50 0.3	5 1.01	-1.92	0.05	
				034 03	2 0.53	-4.90	0.09	
								01 02 05 1 2 9 10
								Disc Eichen Belleun Belleun Anziepischen
								0.1 0.2 0.5 1 2 9 30 Drug Ehring Balloon Belloon Arginplanty
Druj	Eluting Ballo	an va B	lallson Ang	joplasty	Farget	Lesim	1 Reva	01 02 05 1 2 5 X
Drug Stade name	g Eluting Ballo	an an B	lation Any	jioplasty	Target	Lesin Landa	ı Reva	or of or
Drug Stada.net#	Eloting Ballo Information	on va B 10Rmis	lalbon Ang orTanggan	soplasty Satisti	Target	Lesin Landz	a Reva	01 02 05 1 2 5 8 Drog tisting Deliver Refere Arguptony recultarization at 24 months
Drug Stala.nmr*	Elating Ballo Information of	na va B toRinta	allson Ang arline.com	<mark>Soplavty</mark> Satisti MH Lowe & ratio limi	Target o for not t Upper basit 2	Lesin Landz	a Reva	0.1 0.2 0.5 1 2 9 30 Drog Edding Dations (Eddros Anglepistr) recularization at 24 months A <u>th rock ratio and VPs. (3</u>
Drug Zitela tettar Subetwert et al. 22	g Eloting Balloo Informate States	n va B n Rimis TLS	ialboon Ang orTime.com 10 24 months	Santari Santari Mit Lawa & ratio limi 0.73 0.1	Target o for noi Upper boot 4 4 1 22	Lesin Landz -Salusp -1.19	Value 0.23	001 02 03 1 2 3 X Drog Editing Believe Believe Applyinty incularization at 24 meets Millink.note and 92%x57
Drug Sinds name Substant et al. 20 Teps et al. 2008	g Eluting Balloo fadacase.wihit.or Untercorpositional Feasurepositional	TLR TLR	lalloon Ang orTios 2009 14 monto 24 monto	Soplavty Soli Low & rate trat 0.73 0.1 0.22 0.1	Target o for nec Upper Doub d 4 1 23 1 10 46	Lesion Landz -Vistorp -1.19 -4.03	Value 0.23 0.09	Del 62 03 1 2 3 X Desg Edding Bellow Below Assignment recultarization at 24 months https://www.ant.27%.07
Drug Sindla name Schetwert et al. 20 Tope et al 2008 Work et al 2008	g Eluting Balloo Solutions within of Decorresponding Preserveponderal Preserveponderal	n va B n TLR TLR TLR TLR	lalloon Any orTion 2007 19 24 months 24 months 24 months 24 months	Soplasty Statian MH Lows & rate limit 0.73 0.4 0.22 0.1 0.27 0.1	Target cs.firt.nec Upper boolt 2 4 1 23 1 0 46 2 0.60	Lesim handr -Valuep -1.19 -4.83 -3.22	Value 0.23 0.60 0.00	Deg Diding Defines Indexe Approximations incularization at 24 growths Million Approximations (1976)
Drug Stafa.nmr Schenner et al. 20 Topo et al.2008 Werk et al.2008	Elluting Balloo Informate without Decorrepositional Preservepositional Preservepositional	tin via B toRtmas TLR TLR TLR TLR	lalloon Any orTion 2007 19 24 mentle 24 mentle 24 mentle	Soplayty Statian MH Lows & rate limit 0.73 0.4 0.22 0.1 0.27 0.1 0.37 0.1	Target cafor.nm / Upper boost 2 4 3 22 1 8 46 2 8 40 6 0 84	Lesion Landz -Vidrop -1.19 -4.83 -3.22 -2.37	Value 0.23 0.69 0.02	In the second se
Drug Stada.nmp Schenner et al. 20 Tepe et al 2008 Werk et al. 2008	g Eluting Balloo Inducesa estheau Messerepoptical Penserepoptical Penserepoptical	na va B nationas tla tla tla	talboon Ang orTinet.com ro 24 months 24 months 24 months	Soplarity Solid Lowe & ratio limit 0.73 0.1 0.27 0.1 0.37 0.1	Target (a for nm) / Upper ) Until 2 4 3 23 1 8 46 2 8 60 6 0 84	Lesion Lando -Valuep -1.19 -4.83 -3.22 -2.37	Vahar 0.23 0.09 0.02	Deg Editing Defines Thebras to Sequences recularization at 24 months Add table to the sequences Add table to th
Drug Stadu Jame Substant et al. 20 Topo et al. 2005 Work et al. 2005	g Eluting Hallor Induced within of Recomposition Preserves posted	n va B n Runaz TLR TLR TLR TLR	talloon Ang offinst 2009 24 months 24 months 24 months	500 arty 500 arts MBI Lows & ratio limit 0.73 0.1 0.27 0.1 0.37 0.1	Target (1) pper 1 tout 4 1 23 1 8 46 2 0.60 6 0.84	Lesion Landz -Valuep -1.19 -4.03 -3.22 -2.37	Vaha 0 23 0 49 0 40 0 40	Deg Delay Delay Below Below September recularization at 24 months Methods and 97% () 0 1 02 05 1 2 1 0

**CONCLUSIONS** Angioplasty of femoropopliteal and infrapopliteal vascular stenosis with DEB is associated with significantly lower risk of TLR at both 12 and 24 months. DEB use is also associated with 64% higher patency rates compared to BA. Further studies are necessary assess the benefits of mortality with the use of DEB for peripheral vascular interventions.

**CATEGORIES ENDOVASCULAR:** Peripheral Vascular Disease and Intervention

### TCT-168

## Prosthesis-Patient Mismatch after Aortic Valve-In-Valve Implantation: Insights from the Valve-in-Valve International Data (VIVID) Registry

Sabine Bleiziffer,<sup>1</sup> John Webb,<sup>2</sup> Ran Kornowski,<sup>3</sup> David M. Holzhey,<sup>4</sup> Matheus S. Santos,<sup>5</sup> Isaac George,<sup>6</sup> Jan-Malte Sinning,<sup>7</sup> Massimo Napodano,<sup>8</sup> Luis Nombela-Franco,<sup>9</sup> Mayra Guerrero,<sup>10</sup> Henrik Nissen,<sup>11</sup> Tanja Rudolph,<sup>12</sup> Stephen Brecker,<sup>13</sup> Ashish Shah,<sup>14</sup> Petur Petursson,<sup>15</sup> Alfredo Giuseppe Cerillo,<sup>16</sup> Sujay Chandran,<sup>17</sup> Neil Moat,<sup>18</sup> Diego F. Gaia,<sup>5</sup> Seung-Jung Park,<sup>19</sup> Nikolaos Bonaros,<sup>20</sup> Raffi Bekeredjian,<sup>21</sup> Ruediger Lange,<sup>1</sup> Danny Dvir<sup>22</sup> <sup>1</sup>German Heart Center Munich, Munich, Germany; <sup>2</sup>University of British Columbia, Vancouver, Canada; <sup>3</sup>Professor of Cardiovascular Medicine, Rabin Medical Center and Tel Aviv University, Petach Tikva, Israel; <sup>4</sup>University of Leipzig - Heart Center, Leipzig, Germany; <sup>5</sup>Escola Paulista de Medicina - UNIFESP, Sao Paulo, Brazil; <sup>6</sup>Columbia University Department of Surgery, New York, USA; <sup>7</sup>Heart Center Bonn, University Hospital Bonn, Bonn, Germany; <sup>8</sup>University of Padova, Padova, Italy; <sup>9</sup>Cardiovascular Institute, Hospital Clínico San Carlos, Madrid, Spain; <sup>10</sup>Evanston Hospital, Evanston, USA; <sup>11</sup>Odense University Hospital, Odense, Denmark; <sup>12</sup>University Heart Center Cologne, Köln, Germany; <sup>13</sup>St. George's Hospital, London, United Kingdom; <sup>14</sup>Toronto General Hospital, Toronto, Canada; <sup>15</sup>Sahlgrenska University Hospital, Gothenburg, Sweden; <sup>16</sup>Fondazione Toscana, Massa, Italy; <sup>17</sup>Brighton and Sussex University Hospitals, Sussex, United Kingdom; <sup>18</sup>Royal Brompton Hospital, London, United Kingdom; <sup>19</sup>Asan Medical Center, Seoul, Korea, Republic of; <sup>20</sup>Medical University Innsbruck, Innsbruck, Austria; <sup>21</sup>Heidelberg University Hospital, Heidelberg, Germany; <sup>22</sup>St Paul's Hospital, Vancouver, Canada, Vancouver, Canada

**BACKGROUND** Implantation of a transcatheter valve into a degenerated surgical bioprosthesis during aortic valve-in-valve (ViV) procedure may significantly reduce the effective orifice area (EOA) available for blood flow. We sought to investigate the impact of prosthesis-patient mismatch (PPM) on hemodynamics and survival in these patients.

**METHODS** A total of 657 data sets of aortic ViV procedures from the Valve-in-Valve International Data Registry were investigated for the current analysis. Severe PPM after ViV procedure was defined as an indexed EOA < 0.65cm2/m2 patient body surface area (BSA).

**RESULTS** Severe PPM was present in 202 patients after aortic ViV implantation (30.7% total, 61.4% men, STS score 10.6%). The

incidence of severe PPM was higher in patients who received a balloon-expandable device than a self-expandable device (38.4% vs. 21.5%, p<0.0001). Patients with severe PPM were younger (77.2  $\pm$  9.4 years vs. 78.7  $\pm$  8.1, p = 0.05) and had larger body weight (80.9  $\pm$  18.9 kg vs. 72.6  $\pm$  14.1, p<0.0001) than those without severe PPM. In addition, patients with severe PPM had higher aortic mean gradient after the procedure (21.6  $\pm$  10 mmHg vs. 14.1  $\pm$  7.4) and lower aortic valve area (1.03  $\pm$  0.2 cm2 vs. 1.66  $\pm$  0.44), in comparison with patients without severe PPM. Multivariate analysis revealed independent predictors for having severe PPM after aortic ViV: effective orifice area before the procedure (Odds Ratio, OR 0.53 per 1cm2, confidence interval, CI, 0.3-0.94, p=0.03), patient age (OR, 0.97 per 1year increment, CI, 0.94-0.99, p=0.01), using a balloon expandable device (OR, 2.82, CI, 1.78-4.46, p<0.001). In patients who survived aortic ViV implantation procedure, one-year survival was not affected by having severe PPM (93.3% vs. 93.8% in patients without severe PPM, log rank p=0.9).

**CONCLUSIONS** Severe PPM is common after aortic ViV implantation, occurring in approximately one-third of patients. Predictors for severe PPM include young age, stenotic surgical valves and balloon-expandable device implantation. Despite higher valve gradients in patients with severe PPM, one-year survival was similar to those without severe PPM. Therefore, the risk of severe PPM should not discourage operators from performing ViV procedures in inoperable elderly patients.

# CATEGORIES STRUCTURAL: Valvular Disease: Aortic

**KEYWORDS** Patient-prosthesis mismatch, Transcatheter aortic valve replacement, Valve-in-valve

#### TCT-169

## Increased troponin concentrations in patients with stable coronary artery disease are associated with thin-cap fibroatheroma and future major adverse cardiovascular events

Adam J. Brown,<sup>1</sup> Anoop S. Shah,<sup>2</sup> Mateusz Orzalkiewicz,<sup>3</sup> Nick E. West,<sup>4</sup> David E. Newby,<sup>2</sup> Nicholas Mills,<sup>5</sup> Martin R. Bennett,<sup>6</sup> Patrick A. Calvert<sup>3</sup>

<sup>1</sup>University of Cambridge, Cambridge, United Kingdom; <sup>2</sup>University of Edinburgh, Edinburgh, United Kingdom; <sup>3</sup>University Hospitals Birmingham, Birmingham, United Kingdom; <sup>4</sup>Papworth Hospital NHS Trust, Cambridge, United Kingdom; <sup>5</sup>Edinburgh Heart Centre, Edinburgh, United Kingdom; <sup>6</sup>Addenbrooke's Hospital, Cambridge, United Kingdom

**BACKGROUND** Cardiac troponin-I (cTnI) is a marker of myocardial injury and improvements in assay sensitivity allow precise quantification at extremely low serum concentrations. Increased cTnI concentrations are known to predict outcomes in patients with stable coronary artery disease, although the underlying mechanisms remain unknown. As rupture of thin-cap fibroatheroma (TCFA) is thought responsible for the majority of myocardial infarctions, we tested the association between baseline cTnI concentration and plaque classification.

**METHODS** Patients undergoing planned percutaneous coronary intervention (PCI) for stable angina pectoris (n=99) underwent 3-vessel virtual-histology intravascular ultrasound imaging (VH-IVUS, Eagle-Eye Gold, Volcano Corp) before intervention. Virtual-histology (VH)-TCFA were defined as plaques (plaque burden >40%) with >10% necrotic core in contact with lumen for 3 consecutive frames. High-sensitivity cTnI was taken before PCI (ARCHITECT STAT high-sensitivity cTnI assay, Abbott Laboratories, Abbott Park, Il, USA), with patients subsequently stratified into tertiles. Major adverse cardio-vascular events (MACE) were determined at follow-up (median 1,115 days).

**RESULTS** Serum cTnI concentrations for each tertile were; low 2.0 [2.0-3.0]ng/L, intermediate 4.0 [4.0-5.0]ng/L and high 7.0 [6.0-18.0] ng/L. In comparison with the lowest cTnI tertile, highest tertile patients were older ( $67\pm9.7$  vs.  $59.8\pm10.6$ yrs, p=0.002). However, there were no other differences in demographics between these groups, including diabetes mellitus (14.8 vs. 12.0%, p=0.98), hypertension (55.6 vs. 44.0%, p=0.33) and serum creatinine ( $1.00\pm0.15$  vs.  $0.97\pm0.21$ mg/dL, p=0.37). On 3-vessel VH-IVUS, total plaque number (p=0.27), plaque volume (p=0.09), % necrotic core (p=0.17) and % calcification (p=0.21) were similar between lowest and highest tertiles. However, patients in the highest cTnI tertile had a higher number of VH-TCFA, when compared with lowest tertile (2.0 [1.0-2.8] vs. 1.0 [0.0-1.3], p=0.027). On multivariable linear regression analysis, cTnI concentration (p=0.01) was independently associated with